Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN
14. Februar 2024 15:55 ET
|
Tevogen Bio Holdings Inc.
Listing on Nasdaq is expected to provide Tevogen Bio Holdings Inc. increased access to capital to accelerate development of its genetically unmodified off-the-shelf T cell therapy products for large...
Semper Paratus Acquisition Corporation’s Shareholders Approve Business Combination with Tevogen Bio
01. Februar 2024 08:15 ET
|
Semper Paratus Acquisition Corporation
New York, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW, LGSTU), a publicly-traded special purpose acquisition company,...
Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq
24. Januar 2024 16:05 ET
|
Semper Paratus Acquisition Corporation
New York, NY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW), a publicly-traded special purpose acquisition company, today...
Tevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration Statement for Business Combination
05. Januar 2024 08:55 ET
|
Semper Paratus Acquisition Corporation
The pro forma equity value of the portion of the combined company attributable to Tevogen Bio Inc (“Tevogen Bio”) stockholders is an expected $1.2 billion.Tevogen Bio is an advanced-stage specialty...
Semper Paratus Acquisition Corporation Regains Compliance with Certain Nasdaq Listing Requirement
29. September 2023 08:50 ET
|
Semper Paratus Acquisition Corporation
New York, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (Nasdaq: LGST, the “Company”) announced today that it received a letter from the Listing Qualifications Department...
Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc
14. September 2023 17:30 ET
|
Semper Paratus Acquisition Corporation
New York, NY, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (Nasdaq: LGST) (“Semper Paratus”), a publicly traded special purpose acquisition company, today announced the...
Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation
29. Juni 2023 08:05 ET
|
Semper Paratus Acquisition Corporation
Tevogen Bio Inc. (“Tevogen Bio”) is an advanced-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and...